Sector
PharmaceuticalsOpen
₹928Prev. Close
₹921.95Turnover(Lac.)
₹57,701.06Day's High
₹977Day's Low
₹917.0552 Week's High
₹1,63952 Week's Low
₹726.8Book Value
₹415.54Face Value
₹2Mkt Cap (₹ Cr.)
17,438.14P/E
9.42EPS
103.31Divi. Yield
0.6212 May 2025
12:00 AM
Board Meeting
Agenda : Audited Result
12 Feb 2025
12:00 AM
Dividend
Dividend Amount: 1.5
Record Date: 18 Feb, 2025
12 Aug 2024
12:00 AM
AGM
Announcement Date: 12 Aug, 2024
In a statement, NATCO Pharma stated it is confident of addressing all the observations within the stated time frame.
Here are some of the stocks that may see significant price movement today: United Spirits, Biocon, NATCO Pharma, etc.
Quarterly revenue came in at ₹1,287.3 crore, a 16% YoY increase from ₹1,110.3 crore in Q4 FY24, led by robust performance in key segments.
The drug enhances the flow of blood through the lungs, allowing children with PAH to breathe and improve their ability to engage in physical activity.
The company was ensured that the sale of the land and building did not constitute part of its operational assets so that the sale will, in no way, impact the company's business operations
| Y/e 31 Mar( In .Cr) | Mar-2024 | Mar-2023 | Mar-2022 | Mar-2021 |
|---|---|---|---|---|
Equity Capital | 35.8 | 36.5 | 36.5 | 36.5 |
Preference Capital | 0 | 0 | 0 | 0 |
Reserves | 5,556.5 | 4,665.5 | 4,155.4 | 4,054.6 |
Net Worth | 5,592.3 | 4,702 | 4,191.9 | 4,091.1 |
Minority Interest |
| Y/e 31 Mar( In .Cr) | Mar-2021 | Mar-2020 | Mar-2018 | Mar-2017 |
|---|---|---|---|---|
Revenue | 1,653.5 | 1,790.2 | 2,091.3 | 1,958 |
yoy growth (%) | -7.63 | -14.39 | 6.8 | 84.85 |
Raw materials | -500 | -397 | -388.5 | -572.8 |
As % of sales | 30.23 | 22.17 | 18.57 | 29.25 |
Employee costs | -380 | -356.1 | -312.2 | -232.1 |
| Y/e 31 Mar( In .Cr) | Mar-2021 | Mar-2020 | Mar-2018 | Mar-2017 |
|---|---|---|---|---|
Profit before tax | 392.2 | 583.1 | 887.6 | 634.1 |
Depreciation | -115.2 | -98.1 | -65.5 | -53.6 |
Tax paid | -82.7 | -108.6 | -189.4 | -139.3 |
Working capital | -24.9 | 273.2 | 977.8 | 236.8 |
Other operating items |
| Y/e 31 Mar | Mar-2021 | Mar-2020 | Mar-2018 | Mar-2017 |
|---|---|---|---|---|
Growth matrix (%) | ||||
Revenue growth | -7.63 | -14.39 | 6.8 | 84.85 |
Op profit growth | -27.75 | -37.74 | 34.16 | 146.52 |
EBIT growth | -33.16 | -33.09 | 38.47 | 167.7 |
Net profit growth | -34.77 | -32.03 | 41.1 | 180.33 |
| Particulars (Rupees in Crores.) | Mar-2025 | Mar-2024 | Mar-2023 | Mar-2022 | Mar-2021 |
|---|---|---|---|---|---|
Gross Sales | 4,429.5 | 3,998.8 | 2,707.1 | 1,944.8 | 2,052.1 |
Excise Duty | 0 | 0 | 0 | 0 | 0 |
Net Sales | 4,429.5 | 3,998.8 | 2,707.1 | 1,944.8 | 2,052.1 |
Other Operating Income | 0 | 0 | 0 | 0 | 0 |
Other Income | 354.5 | 128.1 | 104.6 | 99 | 103.6 |
Company Name | LTP (₹) | P/E (%) | Mkt.Cap (₹Cr.) | NP Qtr (₹Cr.) | Div.Yield (%) | Sales Qtr (₹.Cr) | Book Value (₹) |
|---|---|---|---|---|---|---|---|
Sun Pharmaceutical Industries Ltd SUNPHARMA | 1,679.7 | 94.05 | 4,02,788.36 | 2,000.46 | 0.95 | 7,107.14 | 101.44 |
Divis Laboratories Ltd DIVISLAB | 6,876 | 82.52 | 1,82,282.67 | 667 | 0.44 | 2,536 | 561.08 |
Cipla Ltd CIPLA | 1,508.7 | 25.32 | 1,21,846.76 | 1,485.4 | 1.06 | 4,254.47 | 397.41 |
Torrent Pharmaceuticals Ltd TORNTPHARM | 3,334.1 | 59.26 | 1,12,908.79 | 474 | 0.96 | 2,385 | 224.33 |
Dr Reddys Laboratories Ltd DRREDDY | 1,291.3 | 20.06 | 1,07,932.29 | 1,200.7 | 0.62 | 5,546.3 | 345.76 |
Figures of Market Capital(Mar Cap), Quarterly Net Profit(NP Qtr) and Quarterly Sales(Sales Qtr) are in ₹ Cr.
Chairman & Managing Director
V C Nannapaneni
Vice Chairman & CEO
Rajeev Nannapaneni
Vice President & Director
PSRK Prasad
President & Director
D Linga Rao
Vice President & Director
Pavan Bhat
Company Sec. & Compli. Officer
Venkat Ramesh
Independent Director
A D Murthy Chavali
Independent Director
B. Lakshminarayana
Independent Director
Kantipudi Suma
Independent Director
Nitin Jain
Independent Director
Vijayabhaskar Dronadula
Natco House,
Road No 2 Banjara Hills,
Telangana - 500033
Tel: 91-040-23547532
Website: http://www.natcopharma.co.in
Email: investors@natcopharma.co.in
12-10-167,
Bharath Nagar,
Hyderbad - 500018
Tel: 91-040-23818475/76/2
Website: www.vccilindia.com
Email: info@vccilindia.com
Summary
Natco Pharma Limited was originally incorporated on 19 September 1981 as private limited company under the name of Natco Fine Pharmaceuticals Private Limited. It became a deemed public company with ef...
Read More
Reports by Natco Pharma Ltd
What is the Natco Pharma Ltd share price today?
What is the Market Cap of Natco Pharma Ltd?
What is the PE and PB ratio of Natco Pharma Ltd?
What is the 52 Week High and Low of Natco Pharma Ltd?
What is the CAGR of Natco Pharma Ltd?
What is the shareholding pattern of Natco Pharma Ltd?
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2025, IIFL Capital Services Ltd. All Rights Reserved
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248, DP SEBI Reg. No. IN-DP-185-2016
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
